{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:23:45Z","timestamp":1790011425842,"version":"4.0.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.msard.2025.106870","type":"journal-article","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T16:14:22Z","timestamp":1763828062000},"page":"106870","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Experience of bortezomib use in refractory autoimmune neurological disorders"],"prefix":"10.1016","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3555-4113","authenticated-orcid":false,"given":"Ekaterina","family":"Popova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7049-2774","authenticated-orcid":false,"given":"Sudheeran","family":"Kannoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6511-3928","authenticated-orcid":false,"given":"Venkitesh","family":"Girish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6295-3223","authenticated-orcid":false,"given":"Jeeva Premaja","family":"Jiju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8782-5472","authenticated-orcid":false,"given":"Saraf Udit","family":"Umesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1023-7098","authenticated-orcid":false,"given":"Gopikrishnan","family":"Unnikrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3333-0933","authenticated-orcid":false,"given":"Siby","family":"Gopinath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7211-9655","authenticated-orcid":false,"given":"Vivek","family":"Nambiar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1340-1768","authenticated-orcid":false,"given":"Anandkumar","family":"Anandakuttan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106870_bib0032","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s00204-014-1316-5","article-title":"Bortezomib-induced peripheral neurotoxicity: an update","volume":"88","author":"Argyriou","year":"2014","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.msard.2025.106870_bib0042","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1007\/s12185-013-1323-y","article-title":"Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review","volume":"97","author":"Besada","year":"2013","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.msard.2025.106870_bib0005","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.2174\/1381612811319220012","article-title":"From Bortezomib to other inhibitors of the proteasome and beyond","volume":"19","author":"Buac","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.msard.2025.106870_bib0044","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.22.01805","article-title":"Bortezomib-dexamethasone, rituximab, and cyclophosphamide as first-line treatment for Waldenstr\u00f6m\u2019s Macroglobulinemia: a prospectively randomized trial of the European consortium for Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"41","author":"Buske","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.msard.2025.106870_bib0011","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4049\/jimmunol.180.1.361","article-title":"Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice","volume":"180","author":"DiLillo","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2025.106870_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577586","article-title":"Bortezomib in anti-N-Methyl-D-aspartate-receptor (NMDA-R) encephalitis: a systematic review","volume":"356","author":"Dinoto","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2025.106870_bib0030","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1002\/sim.7263","article-title":"Analysis of small sample size studies using nonparametric bootstrap test with pooled resampling method","volume":"36","author":"Dwivedi","year":"2017","journal-title":"Stat. Med."},{"key":"10.1016\/j.msard.2025.106870_bib0003","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1002\/eji.200838413","article-title":"Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation","volume":"38","author":"Fissolo","year":"2008","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.msard.2025.106870_bib0029","unstructured":"Flint A. Modified rankin score-9Q (mRS-9Q). Available: https:\/\/www.mdcalc.com\/calc\/10430\/modified-rankin-score-9q-mrs."},{"key":"10.1016\/j.msard.2025.106870_bib0036","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis","volume":"186","author":"Gomez","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2025.106870_bib0010","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1749-6632.2012.06824.x","article-title":"Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis?","volume":"1274","author":"Gomez","year":"2012","journal-title":"Ann N. Acad. Sci."},{"key":"10.1016\/j.msard.2025.106870_bib0035","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.4049\/jimmunol.1301555","article-title":"Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients","volume":"193","author":"Gomez","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2025.106870_bib0045","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40673-021-00129-1","article-title":"Indirect immunofluorescent assay as an aid in the diagnosis of suspected immune mediated ataxias","volume":"8","author":"Hadjivassiliou","year":"2021","journal-title":"Cerebellum. Ataxias."},{"key":"10.1016\/j.msard.2025.106870_bib0013","doi-asserted-by":"crossref","DOI":"10.1093\/braincomms\/fcaa021","article-title":"Bortezomib at therapeutic doses poorly passes the blood-brain barrier and does not impair cognition","volume":"2","author":"Huehnchen","year":"2020","journal-title":"Brain Commun."},{"key":"10.1016\/j.msard.2025.106870_bib0023","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1111\/ene.14325","article-title":"Clinical characteristics and outcome of patients with autoimmune encephalitis: clues for paraneoplastic aetiology","volume":"27","author":"Iorio","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106870_bib0022","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jns.2016.01.006","article-title":"Autoimmune atypical parkinsonism \u2014 a group of treatable parkinsonism","volume":"362","author":"Kannoth","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2025.106870_bib0007","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s10787-021-00863-2","article-title":"Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases","volume":"29","author":"Khalesi","year":"2021","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.msard.2025.106870_bib0008","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.4049\/jimmunol.117.6.2220","article-title":"Subpopulations of chicken B lymphocytes","volume":"117","author":"Lifter","year":"1976","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2025.106870_bib0043","doi-asserted-by":"crossref","DOI":"10.1111\/ejh.13154","article-title":"Efficacy of bortezomib in non-IgM type I cryoglobulinaemic vasculitis: a single-centre retrospective case series","author":"Lobbes","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.msard.2025.106870_bib0006","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nm1763","article-title":"The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis","volume":"14","author":"Neubert","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.msard.2025.106870_bib0033","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2147\/IJGM.S397429","article-title":"Anti-NMDA receptor autoimmune encephalitis: diagnosis and management strategies","volume":"16","author":"Nguyen","year":"2023","journal-title":"Int. J. Gen. Med."},{"key":"10.1016\/j.msard.2025.106870_bib0039","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2015-207947","article-title":"Bortezomib in refractory ANCA-associated vasculitis: a new option?","volume":"75","author":"Novikov","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.msard.2025.106870_bib0004","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.msard.2025.106870_bib0026","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1227\/NEU.0b013e31826a8a56","article-title":"Simple and reliable determination of the modified rankin scale Score in neurosurgical and neurological patients: the mRS-9Q","volume":"71","author":"Patel","year":"2012","journal-title":"Neurosurgery"},{"key":"10.1016\/j.msard.2025.106870_bib0021","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1007\/s00415-017-8599-4","article-title":"Severe refractory CIDP: a case series of 10 patients treated with bortezomib","volume":"264","author":"Pitarokoili","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106870_bib0024","doi-asserted-by":"crossref","DOI":"10.1038\/s41577-021-00543-w","article-title":"Autoantibodies in neurological disease","author":"Pr\u00fcss","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.msard.2025.106870_bib0014","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1089\/neu.2010.1359","article-title":"The treatment of traumatic brain injury with Velcade","volume":"27","author":"Qu","year":"2010","journal-title":"J. Neurotrauma"},{"key":"10.1016\/j.msard.2025.106870_bib0019","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1177\/1756285617721093","article-title":"Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience","volume":"10","author":"Schneider-Gold","year":"2017","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2025.106870_bib0038","doi-asserted-by":"crossref","unstructured":"Sierra-Merlano R.M., Iglesias-Jim\u00e9nez \u00d3., Blanco-Pertuz P.M., et al. Extensive longitudinal transverse myelitis in systemic lupus erythematosus: presentation of a case and literature review. Cureus. 15: e42053. doi:10.7759\/cureus.42053.","DOI":"10.7759\/cureus.42053"},{"key":"10.1016\/j.msard.2025.106870_bib0025","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.nmd.2023.06.010","article-title":"Clinical, neurophysiological and serological clues for the diagnosis of neuromyotonia and distinction from cramp-fasciculation syndrome","volume":"33","author":"Spagni","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.msard.2025.106870_bib0046","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.nmd.2023.06.010","article-title":"Clinical, neurophysiological and serological clues for the diagnosis of neuromyotonia and distinction from cramp-fasciculation syndrome","volume":"33","author":"Spagni","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.msard.2025.106870_bib0001","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40262-018-0679-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of Bortezomib","volume":"58","author":"Tan","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.msard.2025.106870_bib0012","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jamaneurol.2017.3454","article-title":"Bortezomib for Neuromyelitis Optica spectrum disorder: a new therapeutic option for the more severe forms?","volume":"75","author":"Taylor","year":"2018","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2025.106870_bib0028","unstructured":"The Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. 2018. Available: https:\/\/who-umc.org\/media\/164200\/who-umc-causality-assessment_new-logo.pdf."},{"key":"10.1016\/j.msard.2025.106870_bib0017","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3389\/fneur.2020.00188","article-title":"Early bortezomib therapy for refractory anti-NMDA receptor encephalitis","volume":"11","author":"Turnbull","year":"2020","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106870_bib0027","unstructured":"U. S. Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). 2017."},{"key":"10.1016\/j.msard.2025.106870_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1112922","article-title":"In good times and in bad: how plasma cells resolve stress for a life-long union with the bone marrow","volume":"14","author":"Ulbricht","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106870_bib0041","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/rheumatology\/kew286","article-title":"Successful outcome using bortezomib in adult refractory IgA vasculitis: a case report","volume":"55","author":"Van de Perre","year":"2016","journal-title":"Rheumatology"},{"key":"10.1016\/j.msard.2025.106870_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.756941","article-title":"Clinical experience of proteasome inhibitor bortezomib regarding efficacy and safety in severe systemic lupus erythematosus: a nationwide study","volume":"12","author":"Walhelm","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106870_bib0034","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-015-0403-8","article-title":"NF\u03baB signaling drives pro-granulocytic astroglial responses to neuromyelitis optica patient IgG","volume":"12","author":"Walker-Caulfield","year":"2015","journal-title":"J. Neuroinflammation."},{"key":"10.1016\/j.msard.2025.106870_bib0002","first-page":"255","article-title":"The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases","volume":"3","author":"Wang","year":"2006","journal-title":"Cell Mol. Immunol."},{"key":"10.1016\/j.msard.2025.106870_bib0016","article-title":"Clinical features, treatment, and prognostic factors in neuronal surface antibody-mediated severe autoimmune encephalitis","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.msard.2025.106870_bib0040","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1007\/s10067-023-06781-8","article-title":"A narrative review of potential drug treatments for nephritis in children with IgA vasculitis (HSP)","volume":"42","author":"Williams","year":"2023","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.msard.2025.106870_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1220295","article-title":"Case report: anti septin-5-encephalitis as a treatable cause of cerebellar ataxia and psychiatric symptoms","volume":"14","author":"Wischmann","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2025.106870_bib0031","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104353","article-title":"Bortezomib-induced peripheral neuropathy: clinical features, molecular basis, and therapeutic approach","volume":"197","author":"Yang","year":"2024","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.msard.2025.106870_bib0018","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/jamaneurol.2017.1336","article-title":"Safety and Efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder","volume":"74","author":"Zhang","year":"2017","journal-title":"JAMA Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006121?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825006121?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:28:15Z","timestamp":1781076495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825006121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":46,"alternative-id":["S2211034825006121"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106870","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experience of bortezomib use in refractory autoimmune neurological disorders","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106870","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106870"}}